title: Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up.
abstract: Squamous cell carcinoma of the anus (SCCA) is a rare cancer but its incidence is increasing throughout the world, and is particularly high in the human immunodeficiency virus positive (HIV+) population. A multidisciplinary approach is mandatory (involving radiation therapists, medical oncologists, surgeons, radiologists and pathologists). SCCA usually spreads in a loco-regional manner within and outside the anal canal. Lymph node involvement at diagnosis is observed in 30-40% of cases while systemic spread is uncommon with distant extrapelvic metastases recorded in 5-8% at onset, and rates of metastatic progression after primary treatment between 10% and 20%. SCCA is strongly associated with human papilloma virus (HPV, types 16-18) infection. The primary aim of treatment is to achieve cure with loco-regional control and preservation of anal function, with the best possible quality of life. Treatment dramatically differs from adenocarcinomas of the lower rectum. Combinations of 5FU-based chemoradiation and other cytotoxic agents (mitomycin C) have been established as the standard of care, leading to complete tumour regression in 80-90% of patients with locoregional failures in the region of 15%. There is an accepted role for surgical salvage. Assessment and treatment should be carried out in specialised centres treating a high number of patients as early as possible in the clinical diagnosis. To date, the limited evidence from only 6 randomised trials [1,2,3,4,5,6,7], the rarity of the cancer, and the different behaviour/natural history depending on the predominant site of origin, (the anal margin, anal canal or above the dentate line) provide scanty direction for any individual oncologist. Here we aim to provide guidelines which can assist medical, radiation and surgical oncologists in the practical management of this unusual cancer.
authors.affiliation: Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, United Kingdom.
authors.forename: Robert
authors.initials: R
authors.lastname: Glynne-Jones
authors.affiliation: Department of Molecular Medicine and Surgery, Karolinska Instituet and Center for Surgical Gastroenterology, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Per J
authors.initials: PJ
authors.lastname: Nilsson
authors.affiliation: Medical Oncology and Hematology, Felettino Hospital, La Spezia, Italy.
authors.forename: Carlo
authors.initials: C
authors.lastname: Aschele
authors.affiliation: Division of Imaging Sciences & Biomedical Engineering, King's College London, United Kingdom.
authors.forename: Vicky
authors.initials: V
authors.lastname: Goh
authors.affiliation: Radiotherapy Department, Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, France.
authors.forename: Didier
authors.initials: D
authors.lastname: Peiffert
authors.affiliation: Department of Hematology and Medical Oncology, INCLIVA, University of Valencia, Spain.
authors.forename: Andrés
authors.initials: A
authors.lastname: Cervantes
authors.affiliation: Klinik für Tumorbiologie, Freiburg, Germany. Electronic address: clinicalguidelines@esmo.org.
authors.forename: Dirk
authors.initials: D
authors.lastname: Arnold
mesh_terms: D001005:Anus Neoplasms / Q000175:diagnosis* / Q000628:therapy* / Q000821:virology; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis* / Q000628:therapy* / Q000821:virology; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008495:Medical Oncology / Q000592:standards*; D011379:Prognosis; D012955:Societies, Medical
keywords: Anal cancer; Diagnosis; Follow-up; Guidelines; Treatment